Skip to main content
Clinical Trials/NCT02894450
NCT02894450
Completed
Not Applicable

Study of Clinical and Laboratory Variables Associated With a Direct Oral Anticoagulant Bioassay (Xaban) Higher Among Those Aged Over 75 Years, as AOD for Atrial Fibrillation

Nantes University Hospital0 sites70 target enrollmentDecember 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
Nantes University Hospital
Enrollment
70
Primary Endpoint
bioassay direct oral anticoagulants
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

The objective of this study was to investigate whether there is a link between clinical and biological variables and bioassay high xaban in elderly patients as part of an unscheduled hospitalization.

Registry
clinicaltrials.gov
Start Date
December 2014
End Date
December 2015
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 75 years
  • Entering SAU or MPG (Nantes University Hospital) as part of an unscheduled hospitalization for acute or subacute disease (About MPG, will be included patients admitted to the department within 48 hours of calling the doctor)
  • In xaban to entry (dabigatran, rivaroxaban, Apixaban) for non-valvular atrial fibrillation
  • In whom hemostasis tests will be prescribed as part of usual care
  • Patient has given its verbal agreement
  • Exclusion criteria
  • Patients with the following criteria may not be included:
  • Patients refusing to participate in the study
  • Patients under guardianship
  • Inability to obtain the date and time of the last dose of xaban

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

bioassay direct oral anticoagulants

Time Frame: Baseline

Similar Trials